Unknown

Dataset Information

0

Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.


ABSTRACT: Sipuleucel-T was approved by the US Food and Drug Administration on April 29, 2010, as an immunotherapy for late-stage prostate cancer. To manufacture sipuleucel-T, mononuclear cells harvested from the patient are incubated with a recombinant prostatic acid phosphatase (PAP) antigen and reinfused. The manufacturer proposes that antigen-presenting cells exogenously activated by PAP induce endogenous T-cells to attack PAP-bearing prostate cancer cells. However, the lack of demonstrable tumor responses has prompted calls for scrutiny of the design of the trials in which sipuleucel-T demonstrated a 4-month survival benefit. Previously unpublished data from the sipuleucel-T trials show worse overall survival in older vs younger patients in the placebo groups, which have not been shown previously to be prognostic for survival in castration-resistant prostate cancer patients receiving chemotherapy. Because two-thirds of the cells harvested from placebo patients, but not from the sipuleucel-T arm, were frozen and not reinfused, a detrimental effect of this large repeated cell loss provides a potential alternative explanation for the survival "benefit." Patient safety depends on adequately addressing this alternative explanation for the trial results.

SUBMITTER: Huber ML 

PROVIDER: S-EPMC3283534 | biostudies-other | 2012 Feb

REPOSITORIES: biostudies-other

altmetric image

Publications

Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.

Huber Marie L ML   Haynes Laura L   Parker Chris C   Iversen Peter P  

Journal of the National Cancer Institute 20120109 4


Sipuleucel-T was approved by the US Food and Drug Administration on April 29, 2010, as an immunotherapy for late-stage prostate cancer. To manufacture sipuleucel-T, mononuclear cells harvested from the patient are incubated with a recombinant prostatic acid phosphatase (PAP) antigen and reinfused. The manufacturer proposes that antigen-presenting cells exogenously activated by PAP induce endogenous T-cells to attack PAP-bearing prostate cancer cells. However, the lack of demonstrable tumor respo  ...[more]

Similar Datasets

| S-EPMC7831137 | biostudies-literature
| S-EPMC5374023 | biostudies-literature
| S-EPMC3956942 | biostudies-other
| S-EPMC4456994 | biostudies-literature
| S-EPMC4100683 | biostudies-literature
| S-EPMC4876694 | biostudies-literature
| S-EPMC3276755 | biostudies-literature
| S-EPMC6816030 | biostudies-literature
| S-EPMC2767223 | biostudies-other
| S-EPMC3430091 | biostudies-other